Bristol-Myers Squibb (NY:BMY)

Trump’s unpredictable tariff strategy is creating major market shifts. Discover how to read his next moves and uncover hidden investment opportunities before they take off.

My “Two-Step” Plan for Surviving Shaky Markets – and Coming Out Ahead

February 15, 2025

Via InvestorPlace

Topics Government World Trade

Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial

February 13, 2025

Trump’s unpredictable tariff strategy is creating major market shifts. Discover how to read his next moves and uncover hidden investment opportunities before they take off.

Earnings Scheduled For February 6, 2025

February 06, 2025

Via Benzinga

How to Read Trump’s Tariff Playbook – and Prepare for His Next Moves

February 13, 2025

Via InvestorPlace

Topics Government World Trade

Earnings To Watch: Zoetis (ZTS) Reports Q4 Results Tomorrow

February 12, 2025

Animal health company Zoetis (NYSE:ZTS) will be reporting results tomorrow before market open. Here’s what to look for.

Pharmaceutical company Organon (NYSE:OGN) will be reporting earnings tomorrow before market hours. Here’s what investors should know.

Organon (OGN) Q4 Earnings Report Preview: What To Look For

February 12, 2025

Let's have a look at the S&P500 gap up and gap down stocks in today's session.

Gapping S&P500 stocks in Monday's session

February 10, 2025

Via Chartmill

What's Going On With Bristol Myers Squibb Stock On Monday?

February 10, 2025

Bristol Myers Squibb's Breyanzi showed strong efficacy in Phase 2 lymphoma trial, meeting key endpoints. FDA approvals expand its reach in B-cell cancers.

Via Benzinga

Royalty Pharma Earnings: What To Look For From RPRX

February 10, 2025

Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be reporting earnings tomorrow morning. Here’s what to look for.

Bristol Myers Squibb Announces Positive Topline Results for Breyanzi® (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma

February 10, 2025

Despite a Monday sell-off, stocks ended the week higher, and there's evidence that sector rotation is underway; next week's read of inflation may move markets.

MarketBeat Week in Review – 02/03 - 02/07

February 08, 2025

Via MarketBeat

Topics Artificial Intelligence Economy World Trade

Weak Guidance from Bristol-Myers Could Be Creating an Opportunity

February 07, 2025

Bristol-Myers stock fell after earnings, but analysts remain bullish which suggests that any dip in the stock may create a buying opportunity

Via MarketBeat

US Stocks Likely To Open On A Mixed Note: Amazon, Pinterest, Take-Two Among Stocks To Watch

February 07, 2025

U.S. stocks could open mixed on Friday. Newell Brands, Flowers Foods, and Plains All American Pipeline to report earnings.

Via Benzinga

S&P 500 Gains For 3rd Session: Investor Sentiment Improves, But Greed Index Remains In 'Fear' Zone

February 07, 2025

Via Benzinga

Topics Stocks

Bristol Myers Squibb (BMY) Q4 2024 Earnings Call Transcript

February 06, 2025

BMY earnings call for the period ending December 31, 2024.

Via The Motley Fool

Topics Earnings

Stocks Edge Higher, Bank Giants Rally, Palantir Skyrockets: What's Driving Markets Thursday?

February 06, 2025

It's a mixed session on Wall Street, with major indices struggling for direction as investors hold their breath ahead of a key jobs report set for Friday morning. The S&P 500 and the Nasdaq 100 edged...

Via Benzinga

Topics Stocks

Dow Dips 150 Points; Bristol Myers Squibb Issues Weak Outlook

February 06, 2025

Via Benzinga

Topics Stocks

Bristol Myers Squibb Tops Q4 Estimates

February 06, 2025

Bristol Myers Squibb reported strong fourth-quarter earnings but its outlook for 2025 failed to meet expectations.

Via The Motley Fool

Bristol-Myers Squibb Stock Slides On Weak 2025 Outlook, Retail Steps In To Buy The Dip

February 06, 2025

The company announced plans to generate $2 billion in annual cost savings by the end of 2027.

Via Stocktwits

Wondering what's happening in today's S&P500 pre-market session?

February 06, 2025

Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top S&P500 gainers and losers in today's pre-market session.

Via Chartmill

Bristol Myers Squibb Warns Near-Term Impact Due To Generics On 2025 Sales Forecast, Outlines $2 Billion In Additional Cost Cuts

February 06, 2025

Bristol Myers Squibb beat Q4 estimates with $12.34 billion revenue and $1.67 EPS. 2025 guidance lags expectations amid generic headwinds and cost-saving plans.

Via Benzinga

Bristol Myers Wallops Fourth-Quarter Earnings Views. But Shares Plummet 5%.

February 06, 2025

Bristol Myers Squibb stock tumbled Thursday on a light outlook for 2025 following a strong fourth-quarter report.

Via Investor's Business Daily

Bristol-Myers Squibb (NYSE:BMY) Posts Better-Than-Expected Sales In Q4 But Full-Year Sales Guidance Misses Expectations

February 06, 2025

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q4 CY2024, with sales up 7.5% year on year to $12.34 billion. On the other hand, the company’s...

Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024

February 06, 2025

US Stocks Likely To Open Higher Ahead Of Amazon's Earnings: 'Buy The Dip' Mentality Remains Prevalent, Says Analyst

February 06, 2025

U.S. stock futures rose on Thursday following Wednesday's advances as investors digest tariff pauses amid earnings reports.

Via Benzinga

Topics World Trade

Dow Rises Over 300 Points As Nvidia Surges: Investor Sentiment Improves, But Greed Index Remains In 'Fear' Zone

February 06, 2025

Via Benzinga

Topics Stocks

Bristol-Myers Squibb, Amazon And 3 Stocks To Watch Heading Into Thursday

February 06, 2025

Via Benzinga

Earnings To Watch: Bristol-Myers Squibb (BMY) Reports Q4 Results Tomorrow

February 05, 2025

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be reporting results tomorrow before the bell. Here’s what you need to know.